SOV Therapeutics Overview

  • Founded
  • 2009
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $225K
Latest Deal Amount

SOV Therapeutics General Information


Developer of novel therapeutic treatments and oral testosterone replacement therapies. The company's oral T-replacement therapy uses testosterone undecanoate, a pro-drug of testosterone, to overcome many of the problems associated with earlier attempts to formulate and deliver oral testosterone for therapeutic treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Industries
Drug Delivery
Primary Office
  • 101 guymon Court
  • Morrisville, NC 27560
  • United States
+1 (919) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SOV Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 21-Nov-2011 $225K 00000 Completed Startup
1. Angel (individual) 19-Feb-2010 00000 00000 Completed Startup
To view SOV Therapeutics’s complete valuation and funding history, request access »

SOV Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
James Bernstein Ph.D Chief Scientific Officer
Steve Cain Chief Commercial Officer
Om Dhingra Ph.D Founder, Chairman, President & Chief Executive Officer
To view SOV Therapeutics’s complete executive team members history, request access »

SOV Therapeutics Board Members (3)

Name Representing Role Since
Arun Shukla Self Board Member 000 0000
Himanshu Shah SOV Therapeutics Board Member 000 0000
Satinder Sethi Ph.D SOV Therapeutics Board Member & Scientific Advisor 000 0000
To view SOV Therapeutics’s complete board members history, request access »